Login to Your Account



NewCo News: CDG's p28 Shines in Phase I; ASCO Debut a 'Turning Point'

By Jennifer Boggs


Thursday, July 7, 2011
Amid the flood of data reported at last month's American Society of Clinical Oncology (ASCO) meeting, small biotech CDG Therapeutics Inc. emerged from a decade of stealth with the first clinical data for its p28 peptide program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription